# Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/acute-radiation-syndrome-developing-drugs-for-prevention-and-treatment/a8417155-eb91-45ad-9133-c5685df4fb6d

> FDA guidance document: Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment. Issue date: April 19, 2023. Get complete insights and analysis.

---

## Details

- Title: Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-04-19
- Comment Close Date: 2023-07-19
- Last Changed: 2024-04-11
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-1146">FDA-2023-D-1146</a>

## Related Documents

- [Clinical Pharmacology Considerations for Peptide Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8)
- [Endogenous Cushing’s Syndrome: Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/endogenous-cushings-syndrome-developing-drugs-for-treatment/c89a914f-8df3-4543-87dc-697dcbc10611)
- [Dry Eye: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/dry-eye-developing-drugs-for-treatment-guidance-for-industry/c72442af-b5f2-4a62-88b5-4261f9399657)